前列腺癌：转移性前列腺癌中恩扎卢胺的最佳选择。
Prostate cancer: the best fit for enzalutamide in metastatic prostate cancer.
机构信息
Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, Duarte, CA 91010, USA.
Department of Medicine, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112, USA.
出版信息
Nat Rev Clin Oncol. 2014 Sep;11(9):504-6. doi: 10.1038/nrclinonc.2014.128. Epub 2014 Jul 29.
The PREVAIL trial compared enzalutamide and placebo in patients with metastatic castration-resistant prostate cancer who had not received prior chemotherapy, demonstrating an improvement in overall survival and other clinical, radiographic, and biochemical outcomes. Herein, the implications of these data in the rapidly changing landscape of metastatic prostate cancer therapy are discussed.
PREVAIL 试验比较了恩扎卢胺和安慰剂在未接受过化疗的转移性去势抵抗性前列腺癌患者中的疗效，结果显示恩扎卢胺改善了总生存期和其他临床、影像学及生化结局。本文讨论了这些数据在转移性前列腺癌治疗迅速变化的背景下的意义。
Zotero 插件